Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ficlatuzumab + cetuximab
- Development stage
- Unknown
- Lead developer
- AVEO Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ficlatuzumab + cetuximab is an investigational combination therapy consisting of ficlatuzumab, a humanized IgG1 monoclonal antibody targeting hepatocyte growth factor (HGF), and cetuximab, a chimeric IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR). This combination is designed to inhibit two complementary pathways involved in tumor growth and resistance: ficlatuzumab blocks HGF/c-MET signaling, which is implicated as an escape mechanism for EGFR blockade, while cetuximab prevents EGFR activation. Dual inhibition may help overcome resistance in cancers such as head and neck squamous cell carcinoma (HNSCC), particularly in patients who have become refractory to standard therapies. The regimen has shown clinical activity and safety in phase 1 and 2 trials in cetuximab-resistant, recurrent/metastatic HNSCC, notably in HPV-negative disease. Ficlatuzumab is under development by AVEO Oncology; cetuximab is marketed as Erbitux by Eli Lilly[1][2][3][4][5][9].
- Brand names
- Erbitux (for cetuximab)
- Other names
- ficlatuzumab plus cetuximab
02
Targets
EGFR (Epidermal growth factor receptor)HGF (Hepatocyte growth factor)
Beyond the preview
Go deeper on ficlatuzumab + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ficlatuzumab + cetuximab.